Amneal Pharmaceuticals
AMRX
248 hedge funds and large institutions have $1.51B invested in Amneal Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 97 increasing their positions, 73 reducing their positions, and 30 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
33% more repeat investments, than reductions
Existing positions increased: 97 | Existing positions reduced: 73
31% more capital invested
Capital invested by funds: $1.16B → $1.51B (+$354M)
30% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 30
3% more funds holding
Funds holding: 241 → 248 (+7)
2.44% more ownership
Funds ownership: 45.57% → 48.01% (+2.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$17.4M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$12.6M |
| 3 |
WW
Westshore Wealth
Newport Beach,
California
|
+$12.4M |
| 4 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$9.53M |
| 5 |
Morgan Stanley
New York
|
+$9.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$15.4M |
| 2 |
BCP
BlackBarn Capital Partners
New York
|
-$11.3M |
| 3 |
JP Morgan Chase
New York
|
-$5.04M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.59M |
| 5 |
HF
HRT Financial
New York
|
-$3.54M |
AMRX Hedge Fund Activity: Q3 2025 in Review
248 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q3 2025, worth a combined $1.51B — up 31% from $1.16B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new AMRX positions and 30 closed out — a net gain of 9 holders — while 97 added to existing stakes and 73 trimmed.
The largest buyer was BlackRock, adding an estimated $17.4M. The largest seller was Millennium Management, cutting an estimated $15.4M.
- 248 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q3 2025, up from 241 in Q2 2025.
- Funds reported $1.51B of Amneal Pharmaceuticals stock for Q3 2025, up 31% quarter-over-quarter.
- 39 funds opened new Amneal Pharmaceuticals positions in Q3 2025 and 30 closed out, a net change of +9 holders.
- The largest Amneal Pharmaceuticals buyer in Q3 2025 was BlackRock, an estimated $17.4M added.
- The largest Amneal Pharmaceuticals seller in Q3 2025 was Millennium Management, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2025.